Glutamatergic Animal Models of Schizophrenia

Annals of the New York Academy of Sciences

Volumn 1003, Issue , 2003, Pages 131-137

  Moghaddam, Bita ^a   Jackson, Mark E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cognitions; Dopamine; NMDA receptors; Prefrontal cortex; Schizophrenia

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; CYCLOSERINE; DEXTRO SERINE; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; GLYCINE; GLYCINE RECEPTOR ANTAGONIST; KETAMINE; LAMOTRIGINE; LIGAND; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE; PSYCHEDELIC AGENT;

AGITATION; ANIMAL MODEL; APATHY; AUDITORY HALLUCINATION; BEHAVIOR; CHROMOSOME 8P; COGNITIVE DEFECT; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; GENE MAPPING; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HUMAN; MEMORY DISORDER; MUTANT; NEUROTRANSMISSION; NONHUMAN; PARANOIA; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN EXPRESSION; PSYCHOSIS; PSYCHOSOCIAL WITHDRAWAL; SCHIZOPHRENIA; SYMPTOMATOLOGY; WORKING MEMORY;

ANIMALIA;

EID: 0347091934     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1300.065     Document Type: Conference Paper

References (31)

1. LUBY, E. et al. 1959. Study of a new schizophrenomimetic drug-sernyl. Am. Med. Assoc. Arch. Neurol. Psychiatry 81: 363-369.
2. BURNS, R. & L.S. LERNER. 1976. Perspectives: acute phencyclidine intoxication. Clin. Toxicol. 9: 477-501.
3. PEARLSON, G. 1981. Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. Johns Hopkins Med. J. 148: 25-33.
4. KRYSTAL, J.H. et al. 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51: 199-214.
5. JAVITT, D.C. & S.R. ZUKIN. 1991. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148: 1301-1308.
6. KIM, J. et al. 1980. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20: 379-382.
7. ULAS J., C.W. COTMAN. 1993. Excitatory amino acid receptors in schizophrenia. Schizophr. Bull. 19: 105-117.
8. OLNEY, J. & N. FARBER. 1995. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52: 998-1007.
9. COYLE, J. 1996. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev. Psychiatry 3: 241-253.
10. TAMMINGA, C.A. 1998. Schizophrenia and glutamatergic transmission. Crit. Rev. Neurobiol. 12: 21-36.
11. GREENBURG, B.D. & D.S. SEGAL. 1985. Acute and chronic behavioral interactions between phencyclidine (PCP) and amphetamine: evidence for a dopaminergic role in some PCP-induced behaviors. Pharmacol. Biochem. Behav. 23: 99-105.
12. SCHMIDT, H.W. et al. 1989. Effects of intrastriatal blockade of glutamatergic transmission on the acquisition of T-maze and radial maze tasks. J. Neural Transm. 78: 29-41.
13. STEINPREIS, R. et al. 1994. The effects of haloperidol and clozapine on PCP and amphetamine induced suppression of social behavior. Pharmacol. Biochem. Behav. 47: 579-585.
14. VERMA, A. & B. MOGHADDAM. 1996. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16: 373-279.
15. MANSBACH, R.M. & M. GEYER. 1989. Effects of phencylidine and phecylidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2: 299-308.
16. ADLER, C.M. et al. 1999. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psychiatry 156: 1646-1649.
17. RAINEY, J.J. & M. CROWDER. 1975. Prolonged psychosis attributed to phencyclidine: report of three cases. Am. J. Psychiatry 10: 1076-1078.
18. BAKKER, C.B. & F.B. AMINI. 1961. Observations on the psychotomimetic effects of sernyl. Comp. Psychiatry 2: 269-280.
19. KEITH, V.A., R.S. MANSBACH & M. A. GEYER. 1991. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol. Psychiatry 30: 557-566.
20. KRYSTAL, J. et al. 1995. Modulating ketamine-induced thought disorder with lorazepam and haloperidol in humans. Schizophr. Res. 15: 156a.
21. JAVITT, D.C. 2002. Glycine modulators in schizophrenia. Curr. Opin. Investig. Drugs 3: 1067-1072.
22. GOFF, D.C. et al. 1999. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. [see comments]. Arch. Gen. Psychiatry 56: 21-27.
23. HERESCO-LEVY, U. et al. 2002. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiatry 159: 480-482.
24. LIU, J. & B. MOGHADDAM. 1995. Regulation of glutamate efflux by excitatory amino acid receptors: evidence for tonic inhibitory and phasic excitatory regulation. J. Pharmacol. Exp. Ther. 274: 1209-1215.
25. MOGHADDAM, B. et al. 1997. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17: 2921-2927.
26. ANAND, A. et al. 2000. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch. Gen. Psychiatry 57: 270-276.
27. MOGHADDAM, B. & B. ADAMS. 1998. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281: 1349-1352.
28. Krystal, J.H., W. Abi-Saab, E. Perry, et al. 2003. Interaction of ketamine and an mGluR2/3 agonist in healthy volunteers. Biol. Psychiatry 53: 312.
29. STEFANSSON, H. et al. 2002. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71: 877-892.
30. OZAKI, M. et al. 1997. Neuregulin-beta induces expression of an NMDA-receptor subunit. Nature 390: 691-694.
31. MOHN, A.R. et al. 1999. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98: 427-436.